The 9.73x trailing EV/EBITDA compressing to 3.45x forward appears to assume EBITDA roughly triples, a step-change that would require both the gross margin step-down from the 64.8-67.8% range to 53.6-56.8% and the revenue contraction to reverse simultaneously. At 1.02x P/B the shares look nominally cheap versus Procore's 6.52x and even EVERTEC's 2.65x, but that comparison is likely misleading here given the goodwill concentration discussed below, and the 98.44x P/FCF suggests the market is applying an EV/Sales lens (1.73x) rather than crediting reported free cash flow.

The true earning-power metric here is operating margin adjusted for stock-based compensation of $3.2-7.4M per quarter, which repeatedly equals or exceeds reported operating income; on that basis core profitability appears closer to break-even than the mid-single-digit prints suggest. Headline net margin should be disregarded entirely, since the 193.7% reading in 2024Q4 reflects a $117.9M non-operating credit rather than operations, and the 10.7% net margin in 2026Q3 against a negative operating margin reinforces that the bottom line is being rescued by items outside the core business.

Asset turnover has been pinned in a narrow 0.06-0.09 band despite roughly $156M of net acquisition outflows across 2025Q4 and 2026Q2, suggesting incremental acquired revenue has not translated into meaningful incremental sales per dollar of assets. The 27.4% ROE in 2024Q4 is not evidence of compounding returns; it was driven by the same non-operating credit that produced a 193.7% net margin, and ROE has since collapsed to 0.1-2.5%, which points more toward a decay pattern than a scaling one.

The trajectory from 10.52x coverage in 2025Q4 to 4.95x, alongside a D/EBITDA jump from 0.91x to 13.19x, suggests debt service is becoming measurably less comfortable just as operating income has turned negative in the latest quarter; investors should monitor whether coverage continues to erode if EBITDA follows the operating margin trend. What makes this pattern notable is that the leverage appears to have been raised to fund approximately $137M of buybacks rather than expansion, which is a structurally different credit profile than debt raised against growth assets.

A 1.21x current ratio reads as adequate in isolation, but the composition matters: with cash at $2.6M the near-term liability coverage appears to rest on receivables, and a DSO of 89 days (versus a 77-93 day range over the period) means those receivables would need sustained collection to be relied upon under stress. The absence of inventory means the quick ratio equaling the current ratio is expected for this model, so the stress test for this balance sheet is really about whether accounts receivable convert on schedule and whether the revolving capacity implied by the 2026 debt build remains available on terms the company can service.